EP Patent

EP3968998A1 — Dosing of kras inhibitor for treatment of cancers

Assigned to Amgen Inc · Expires 2022-03-23 · 4y expired

What this patent protects

Provided herein are methods of administering a KRAS G12C inhibitor, namely AMG-510, to a cancer subject. CA19-9 and CEA Biomarkers.

USPTO Abstract

Provided herein are methods of administering a KRAS G12C inhibitor, namely AMG-510, to a cancer subject. CA19-9 and CEA Biomarkers.

Drugs covered by this patent

Patent Metadata

Patent number
EP3968998A1
Jurisdiction
EP
Classification
—
Expires
2022-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.